12:00 AM
 | 
Nov 24, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 11/21 cls
Alimera Sciences Inc. (NASDAQ:ALIM) Summer Street Jim Molloy New Buy 2% $5.37
Molloy initiated coverage with a $12 target ahead of an anticipated U.S. launch in 1Q15 of Alimera's diabetic macular edema (DME) product Iluvien fluocinolone acetonide intravitreal implant. Alimera...

Read the full 437 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >